GIANT is an open-label, multi-center, randomized, perioperative (neoadjuvant followed by adjuvant), phase 2 trial with a safety lead-in phase to investigate the feasibility, safety and tolerability, and establish the biological activity of nivolumab with or without relatlimab in patients with isocitrate dehydrogenase (IDH) wildtype newly diagnosed glioblastoma (ndGBM).

开始日期2025-06-01

申办/合作机构

Duke University

NCT06683755

/ Not yet recruiting临床1/2期IIT

Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)

To determine the recommended Phase IIa dose (RP2D) of the triplet combination.
To determine the safety and efficacy of the combination at the RP2D.

开始日期2025-05-01

申办/合作机构

The University of Texas MD Anderson Cancer Center

NCT05629546

/ Recruiting临床1期IIT

Phase I Study of Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors

This is a Phase 1 open-label, study designed to characterize the safety, tolerability, and preliminary anti-tumor activity of memory-like natural killer cells (ML NK) in combination with nivolumab and relatlimab in subjects with advanced and/or metastatic melanoma. There will be two arms to test the variables of ML NK cell source. ML NK cells from an autologous source will be used for Arm 1, and ML NK cells from an allogeneic source will be used for Arm 2. The investigators hypothesize that ML NK cells from either an autologous source or allogeneic source are safe and tolerable in subjects with advanced and/or metastatic melanoma.

开始日期2024-11-06

申办/合作机构

Washington University School of Medicine

[+2]

100 项与瑞拉利单抗相关的临床结果

登录后查看更多信息

100 项与瑞拉利单抗相关的转化医学

登录后查看更多信息

100 项与瑞拉利单抗相关的专利（医药）

登录后查看更多信息

107

项与瑞拉利单抗相关的文献（医药）

2025-12-31·OncoImmunology

Impact of steroid dose and timing on efficacy of combination PD-1/CTLA-4 blockade

Article

作者: Czapla, Juliane Andrade ; Burnette, Hannah R. ; Cui, Can ; Curkovic, Nina B. ; Lawless, Aleigha R. ; Irlmeier, Rebecca ; Sullivan, Ryan ; Ye, Fei ; Johnson, Douglas B. ; Bai, Xue

With the increasing use of immune checkpoint inhibitors (ICIs) in combination regimens and in earlier stages of advanced melanoma, the effective management of immune-related adverse events (irAEs) is key to balancing immunotherapy efficacy and toxicity. Conflicting evidence exists on possible detrimental effects of immunosuppression with corticosteroids for irAEs on ICI effectiveness. We conducted a multicenter, retrospective cohort study of immunotherapy-naïve advanced melanoma patients undergoing treatment with ipilimumab and nivolumab and a small cohort treated with nivolumab/relatlimab. We utilized univariate tests to assess response, PFS, and OS based on presence of irAE, receipt of steroids for irAEs, peak dose, and time-to-steroid, as well as multivariable analysis for response, OS, and PFS in patients receiving steroids for irAEs. Among 226 total ipilimumab/nivolumab patients, those without irAEs had poorer PFS and OS compared to irAE groups regardless of steroid administration. In subgroup analysis of patients receiving steroids for an irAE, increased time-to-steroid was significantly associated with improved response (aOR, 1.026 p = 0.0005), PFS (aHR, 0.986 p = 0.001), and OS (aHR, 0.983 p = 0.0008). Higher peak steroid dose was significantly associated with poorer PFS (aHR, 1.002 p = 0.005), and OS (aHR, 1.002 p = 0.003). Use of additional immunosuppressants was associated with poorer OS (aHR, 1.941 p = 0.018). Cumulative dose was not significantly associated with outcomes. Among 42 additional patients treated with nivolumab/relatlimab, irAEs were significantly associated with improved PFS/OS, which appeared to be slightly mitigated by steroid administration; dosing relationships were limited by small numbers.

2025-06-01·American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

Beyond Checkpoint Inhibition: Keeping Therapeutic Options Open

Review

作者: Hundal, Jasmin ; Luke, Jason J. ; Schollenberger, Megan D. ; Funchain, Pauline ; Lipson, Evan J. ; Joshi, Urvashi Mitbander ; Mata, Jonaphine R. ; Warrier, Govind

Combination immune checkpoint inhibitor therapy (ICI) with ipilimumab (anti–cytotoxic T-lymphocyte–associated protein 4) + nivolumab (anti–PD-1) in untreated, metastatic melanoma has achieved a ten-year melanoma-specific survival of 52%. However, approximately 40%-55% of patients with metastatic melanoma have primary resistance and do not initially respond to anti–PD-1, and an additional 25% of patients develop secondary resistance, exhibiting an initial response followed by disease progression. In PD-1–refractory melanoma, treatment options are limited. Addition of ipilimumab, relatlimab (anti-LAG3), or lenvatinib (VEGFR TKI) has minimal to modest efficacy. Switching to targeted BRAF/MEK inhibition improves survival for BRAF-mutant disease. MEK and KIT inhibitors have limited activity in NRAS- and KIT-mutant metastatic melanoma, respectively. Recently, personalized, autologous tumor-infiltrating lymphocyte therapy has become a US Food and Drug Administration–approved second-line option; lifileucel demonstrates durable response (approximately 30%) in heavily pretreated, metastatic melanoma. Emerging therapeutics that show promising clinical benefit in ongoing clinical trials include novel engineered oncolytic viral and human leukocyte antigen (HLA)–restricted immune-mediated T-cell therapies. As a therapy which is limited to patients who are HLA-A*02:01, T-cell receptor (TCR) engineered T cells (TCR-T) iterates on personalized adoptive cell transfer, and immune mobilizing monoclonal TCRs against cancer are CD3 bispecifics that bind glycoprotein 100 (tebentafusp, approved for metastatic uveal melanoma) or PRAME to activate T cells. Finally, in patients at high risk for immune-related adverse events (irAEs), ICI should still be considered. ICI may be given with modified immunosuppression in patients with autoimmune disease or previous organ transplantation. Cumulative data support safe administration in older patients and in ICI rechallenge for patients with previous irAE.

2025-04-10·JOURNAL OF CLINICAL ONCOLOGY

Erratum: First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data

Article

作者: Long, Georgina V. ; Lipson, Evan J. ; Ejzykowicz, Flavia ; Grob, Jean-Jacques ; Schadendorf, Dirk ; Sakkal, Leon A. ; Garcia-Horton, Viviana ; Lao, Christopher ; Tawbi, Hussein ; Salvatore, Anthony ; Xin, Yiqiao ; Ascierto, Paolo A. ; Moshyk, Andriy ; Zhou, Zheng-Yi ; Keidel, Sarah ; Hodi, F. Stephen ; Palaia, Jennell ; Larkin, James ; McDonald, Laura ; Patel, Divya

159

项与瑞拉利单抗相关的新闻（医药）

2025-04-09

·VIP说

肿瘤免疫治疗策略2.0

# 本篇笔记仅基于公开资料和信息撰写、为个人观点、供学术交流所用、不构成任何建议 #我用了差不多一个月的时间，看了几十家代表公司的产品线、几千篇研报和点评、几万个注册临床试验，想要看清楚肿瘤免疫治疗棋局的现状和未来。这不符合我的本性，我是宁可去无人区探险，也不想投入毫厘铢锱不能差错的极致内卷中。但是，现实就是，现在和未来很长一段时间内，免疫检查点抑制剂都会是肿瘤治疗的基石，即使MNC们早就已经布局于免疫检查点抑制剂之外甚至肿瘤治疗之外，国内大多数药企还有一段国产替代的长路要走。既然不能提前退休，只能强忍着非常严重的内卷PTSD看棋局，这种不适感压制了我的段子手级别语言天赋，所以这篇笔记会写的非常......直白。我个人给免疫治疗策略1.0的定义，就是大家手里都有个PD-(L)1抑制剂产品。全球已经有32个/国内已经有24个PD-(L)1抑制剂产品上市。图片引用来自“IO笔记”。至于免疫治疗策略2.0，就是如何进一步迭代和升级。PD-(L)1抑制剂产品本身的迭代和升级，目前大家的策略非常一致，改良单抗本身没能创造出什么奇迹，就开发双抗/多抗和复方，以及皮下注射、口服小分子、ADC等新剂型。双抗/多抗和复方本质类似于联合给药方案，所以放到后面再说。开发皮下注射剂型看上去是个捷径，不过如果大家的目标是国际市场，可能会有专利侵权风险：阿斯利康7.5亿美元引进Alteogen透明质酸酶技术，后者深陷侵权风险口服小分子PD-(L)1抑制剂，我是没有“小药说药”那么关注，而且似乎已经冷却：靶向PD-1/PD-L1小分子药物的研究进展至于PD-(L)1 ADC，反正已经热闹起来：靶向PD-L1 ADC：辉瑞首次国内申报临床！复宏汉霖、映恩生物“勇攀高峰”此外，国内外很多家药企已经想开了，不搞什么伪创新药，帕博利珠单抗核心专利将于2028年到期，直接开发生物类似药。国内外我已经数出来10个帕博利珠单抗类似药在做注册临床试验了，还有3个纳武利尤单抗生物类似药。更广谱的迭代和升级策略，就是以PD-(L)1抑制剂产品为基石，开发各种联合给药方案。汇总信息还是医药魔方做得最漂亮（反正我下载了PPT）：PD-1/PD-L1抑制剂中美获批及全球注册性临床试验15年动态趋势医药魔方PPT中部分内容截图：类似的汇总信息报告和点评很多，都能让大家一眼看清楚肿瘤免疫治疗棋局已经内卷到什么地步，看完不但没有思路，反而更加焦虑了。所以我们还是采用最简单高效的fast follow的老办法，看看几十家代表公司的肿瘤免疫治疗产品线，看看follow谁家的具体策略最适合自家。1. 默沙东/默克帕博利珠单抗(PD-1单抗)，长期被群殴和围攻的药王，王冠太重。在肿瘤领域，默沙东/默克不断探索和拓展其各种联合给药方案，并且积极布局复方和皮下等新剂型，双抗等新产品，以求夯实其在肿瘤领域的领先地位。复方主要是MK-1308A(PD-1+CTLA-4，Pembrolizumab+Quavonlimab)，MK-7684A(PD-1+TIGHT，Pembrolizumab+Vibostolimab)，MK-4280A(PD-1+LAG-3，Pembrolizumab+favezelimab)，2024年12月宣布终止开发后两个，目前只有MK-1308A还在推进。皮下剂型MK-3475A的III期临床试验刚官宣成功。近年来，默沙东/默克的肿瘤产品线重点已经布局于免疫检查点抑制剂之外，但免疫检查点抑制剂还是肿瘤治疗的基石，肿瘤领域且没有禁忌症，什么新产品都尝试联联看，就像吃什么菜都要配一碗白米饭。看帕博利珠单抗适应症布局是一项极其艰巨的工作，我差不多用了半个月时间，剩下几十个产品用了剩下的半个月时间。太多了。不仅因为默沙东/默克财大气粗，有把握的III期试验开几百个，没把握的I-II期试验和IIT开几千个，更因为帕博利珠单抗是基石中的基石，米饭中的白米饭，其他药企开发联合给药方案也是首选帕博利珠单抗。即使默沙东/默克没有布局，其他药企也会填空，所有瘤种所有适应症，完全没有空缺。最后得去翻默沙东/默克官网的PPT，才能找出他家真正的主线。如果布局图里出现了个别空缺，那也是某些III期临床试验失败导致的，绝不是没人尝试过填空。比如大家都吃过瓜的LEAP系列。但是有三个瘤种，即著名的冷肿瘤们，卵巢癌、胰腺癌、前列腺癌，所有药企都是屡战屡败+屡败屡战。先驱栽坑里那是代价，后来者再盲目跳坑，我可能忍不住嘲笑了，如果不是颠覆性作用机制的新药，建议不要再尝试将免疫治疗用于这几个瘤种。2. BMS纳武利尤单抗(PD-1单抗)，没能问鼎药王，所以在此基础上早早开发出皮下注射剂型，与伊匹木单抗(Ipilimumab, CTLA-4)联合方案，与Relatlimab(LAG-3单抗)联合方案，甚至开发了复方OPDUALAG(Nivolumab+Relatlimab)，均已成功获批多个适应症。也曾在TIGHT、IDO等靶点药物联合方案上栽过跟头，最新产品是复方BMS-986489(PD-1+fucosyl-GM1, Nivolumab+BMS-986012)。近年来，BMS的肿瘤产品线重点也已经布局于免疫检查点抑制剂之外。但免疫检查点抑制剂还是肿瘤治疗的基石，主动或被动开发联合方案也非常多。3. 罗氏阿替利珠单抗(PD-L1单抗)，其实已经算差异化开发了，靶点从PD-1换成了PD-L1。阿替利珠单抗是早早成功开发了皮下注射剂型。之后开发双抗时换回PD-1单抗，包括Tobemstomig(RO7247669, PD-1/LAG-3)，Lomvastomig(PD-1/TIM-3, RO7121661)。罗氏在肿瘤免疫治疗方面不算成功，主要是因为阿替利珠单抗与Tiragolumab(TIGHT单抗)的联合方案投入太大，受伤太深。但是深挖一下新技术平台，还能翻出来PD1-IL2v，PDL1 LNA等产品。值得注意的是，阿替利珠单抗用于三阴性乳腺癌非常波折，各种姿势的III期临床试验失败和撤回适应症，鉴于特瑞普利单抗在同一适应症里取得过成功，咱们不能说三阴性乳腺癌不适合免疫治疗，但PD-1单抗似乎比PD-L1单抗强一些。肾癌、尿路上皮癌、头颈癌、宫颈癌里也有类似情况，建议谨慎选择PD-L1单抗。4. 阿斯利康度伐利尤单抗(PD-L1单抗)，早期策略和BMS类似，开发皮下注射剂型，还有和替西木单抗(Tremelimumab, CTLA-4)的联合给药方案。后来者的好处就是可以避开先驱们栽过的坑，适应症开发都比较顺利。现在已经不做复方了，直接换双抗，Volrustomig(PD-1/CTLA-4)，Sabestomig(PD-1/TIM-3)，Rilvegostomig (PD-1/TIGHT)。发起IO+ADC潮流的应该就是他家，而且他家明显艺高人胆大，最偏爱Rilvegostomig (PD-1/TIGHT)，这是要死磕TIGHT靶点的节奏。5. 辉瑞、吉列德、再生元、GSK、Incyte、BIOCAD可以说，辉瑞几乎错了肿瘤免疫治疗浪潮。Avelumab(PD-L1单抗)开发顺位非常靠后，所以从超级冷门小适应症下手—皮肤默克尔细胞癌，弯道超车获批上市后，目前仅在膀胱癌领域取得成功（联合阿昔替尼用于肾癌一线是基于PFS成功附条件获批，但是OS失败，现在很尴尬；用于非小细胞肺癌、头颈癌和胃癌都是全面失败）。后来一度想悄悄开发PD-1单抗皮下注射剂型Sasanlimab（未获批上市），最终还是抢跑PF-08046054(PD-1 ADC)。后来者后来到辉瑞这个地步，如果还不愿赌服输，就得这么另辟蹊径。但是Sasanlimab有点过，首个适应症居然选择联合BCG用于非肌层浸润性膀胱癌，之前帕博利珠单抗和纳武利尤单抗都挑战失败的适应症，全球均未有免疫检查点抑制剂类产品获批。吉列德也是后来者，但是通过收购Arcus获得了赛帕利单抗(Zimberelimab，PD-1单抗)，果然顺产没有顺手快。在国内，赛帕利单抗用于经典型霍奇金淋巴瘤和晚期宫颈癌已获批上市。但是他家的联合给药方案，目前以Domvanalimab(TIGHT单抗)为主，又是一个死磕TIGHT靶点的。再生元不算后来者，Cemiplimab(PD-1单抗)虽然不算先驱，但是通过小适应症—皮肤鳞状细胞癌和皮肤基底细胞癌，早早弯道超车获批上市。他家毕竟是资深肿瘤免疫疗法biotech，联合给药方案非常多，目前以联合Fianlimab(LAG-3单抗)为主。GSK不算后来者也不算先驱，多塔利单抗(Dostarlimab，PD-1单抗) 通过小适应症—dMMR/MSI-H子宫内膜癌，早早弯道超车获批上市，之后仅专注于子宫内膜癌、结直肠癌和头颈癌，坚定的反内卷思维，深得我心。Incyte真不容易，当初为了卡瑞利珠单抗和恒瑞分分合合，最后终于拥有了自己的Retifanlimab(PD-1单抗)。跟辉瑞类似，因为Retifanlimab开发顺位非常靠后，所以从超级冷门小适应症下手—皮肤默克尔细胞癌，弯道超车获批上市。后来居然又被再鼎引入中国继续开发，反正各种不容易。再看Incyte产品线，始终专注于肿瘤免疫疗法，口服PD-L1，PD-1/LAG-3双抗、PD-1/TGF-βRII双抗均有布局。Prolgolimab(PD-1单抗)由俄罗斯药企BIOCAD开发，获得俄罗斯卫生部批准上市，用于治疗转移性黑色素瘤。在两国总理的共同见证下，由上药集团引进入国内共同开发，上药集团不愧是一流国企，非常正确。值得一提的是，Prolgolimab都这么正确了也没有躺平，继续开发复方BCD-217(Prolgolimab+Nurulimab，PD-1+CTLA-4)，还开发了帕博利珠单抗生物类似药。6. 其他外企艾博维：Budigalimab(PD-1单抗)Budigalimab绝对算后来者，我个人高度怀疑艾博维是为了联合其他自家真爱的新产品才被迫开发了基石。到现在最高开发阶段II期临床试验。强生：Cetrelimab(PD-1单抗)也不知道这个产品是不是和辉瑞的Sasanlimab高度类似，首个适应症居然也选择非肌层浸润性膀胱癌，但联合了自家TAR-200，我个人觉得就是为了陪衬TAR-200。2025年1月15日，强生宣布递交TAR-200的上市申请，用于治疗卡介苗（BCG）不应答的高危非肌肉侵袭性膀胱癌（HR-NMIBC）伴原位癌（CIS）患者。此次递交通过实时肿瘤审评（RTOR）项目，允许FDA在完全申请正式递交之前就开始审评以加快进度。 TAR-200为一种膀胱内局部给药的新型递送系统，采用一种双重小片设计，材质为硅聚合物半透小管，吉西他滨在膀胱持续缓慢释放。BI：Ezabenlimab(PD-1单抗)反正我个人高度怀疑BI是为了联合其他自家真爱的新产品才被迫开发了基石。到现在最高开发阶段II期临床试验。安进：Zeluvalimab(PD-1单抗)在安进最新的产品线信息里已经找不到Zeluvalimab了，但是找到了纳武利尤单抗生物类似药，预期2025年获批上市。放弃死磕开发顺位过于滞后的伪创新药，拥抱生物类似药，拥抱效率和利润，毕竟肿瘤免疫治疗也不是安进公司的主线，顶多用来联合其他自家真爱的新产品。Agenus：Botensilimab(PD-1单抗)Agenus还算比较重视Botensilimab，但主要是为了配合新一代产品—Balstilimab(CTLA-4单抗)，声称可以将冷肿瘤转化为热肿瘤。首个适应症选择联合Balstilimab用于non-MSI-H结直肠癌。坚定的反内卷思维，深得我心。BioNTech：BNT327(PD-L1/VEGF双抗)等收购普米斯生物等biotechs，跳过肿瘤免疫治疗1.0时代，直接飞跃至2.0时代潮头，拥有各种最热门双抗和ADC，又是顺产哪有顺手快的成功案例和典型代表。不过最新的消息是BNT311(PD-L1/4-1BB双抗)退回Genmab，这不是一个好消息，真正成功的双抗也不多。BioNTech的策略虽然有抄袭AZ，但非常清晰明确，值得学习。先分析免疫检查点抑制剂单药或既往的联合给药方案，在全球范围内获批过哪些适应症，还有哪些细分人群中有未被满足的临床需求，既往放弃开发或开发失败适应症的困难在哪里。再分析或补充自家产品线里的产品，是否有新颖的作用机制可能攻克之前的困难。最后设计BNT327的临床开发计划：第一步，联合化疗去攻克确定性高、能快速实现高市场价值的适应症；第二步，联合各种新颖作用机制的新产品，填补之前未被满足的临床需求；第三步，探索更多、更新的联合给药方案和适应症。篇幅原因，写完外企部分已经快5000字了，改天再写国内企业部分。信息量过大，CPU干烧到头晕，所有重点点到即止，如有疏漏错误，请大家多包涵。# 本篇笔记仅基于公开资料和信息撰写、为个人观点、供学术交流所用、不构成任何建议 #

抗体药物偶联物免疫疗法生物类似药

2025-03-09

·蒲公英Ouryao

谁家抗癌药最畅销？2024全球肿瘤药企TOP3出炉

随着科技的飞速发展和人类对癌症认知的不断深入，2024年的全球制药肿瘤行业迎来了新一轮的洗牌。今天，就让我们一起揭晓2024年全球制药肿瘤行业排名TOP10，看看TOP3的企业是哪些？哪些产品又占据了前三甲？在肿瘤产品市场前三甲的激烈排位争夺战中，默沙东凭借史上最畅销的肿瘤药物K药强势卫冕。与此同时，BMS与罗氏之间的竞争态势愈发白热化。靠着实体瘤和血液瘤两大板块的多元扩张，两者的肿瘤业务收入都增长到了270亿美元量级，在肿瘤市场中形成了强有力的竞争格局，也为整个行业的发展注入了新的活力与变数。图 2024年全球制药巨头肿瘤业务排名TOP10 （来源：医药魔方） PART.01 2024年全球制药肿瘤业务TOP3企业 NO.3 罗氏凭借着实体瘤和血液瘤板块的双轮驱动增长，罗氏作为肿瘤霸主的辉煌再度闪耀，2024年其肿瘤业务收入达237.44亿瑞士法郎（约270.40亿美元），与BMS的肿瘤业绩已相差无几。 Tecentriq（阿替利珠单抗）和Perjeta（帕妥珠单抗）依然是罗氏实体瘤领域的两大拳头产品。在一众实体瘤产品中，治疗乳腺癌的HER2单抗复方制剂Phesgo（帕妥珠单抗曲妥珠单抗皮下注射制剂）的增长表现较为亮眼，同比增长62%至17.40亿瑞士法郎（约19.82亿美元）。此外，PI3Kα抑制剂Itovebi的获批也为罗氏的乳腺癌产品线注入了新的活力。在乳腺癌领域持续领跑的罗氏正通过外部创新巩固其优势。2024年9月，罗氏旗下基因泰克将以8.5亿美元的首付款收购锐格医药的下一代CDK抑制剂，这与罗氏现有的HER2、PI3K等靶向药物形成了更全面的产品矩阵。血液瘤领域，革新弥漫性大B细胞淋巴瘤（DLBCL）一线治疗的CD79b ADC药物Polivy展现不错的产品力，以11.21亿瑞士法郎（约12.77亿美元）的销售额跻身重磅炸弹行列。两款主打适应症差异化的CD3/CD20双抗Columvi和Lunsumio还在起量阶段。通用型CAR-T疗法的开发有望进一步强化罗氏在血液瘤领域的实力。2024年11月，罗氏以15亿美元收购了Poseida Therapeutics。罗氏认为，基于后者的技术平台打造的通用型CAR-T疗法有潜力成为各治疗领域的同类最佳产品。 NO.2 BMS BMS的肿瘤业务十分庞大，实体瘤与血液瘤两大板块齐头并进。Opdivo（纳武利尤单抗）仍是BMS在实体瘤领域的扛大旗者，2024年销售收入93.04亿美元，同比增长3%。 BMS始终跑在免疫联合赛道的前沿。Yervoy（伊匹木单抗）销售额稳健增长，O药+Y药的免疫双子星组合还于2024年在中国迎来了新适应症的全球首批，一线治疗MSI-H/dMMR结直肠癌患者。PD-1+LAG-3组合疗法Opdualag（纳武利尤单抗+瑞拉利单抗）离重磅炸弹只有一步之遥。新一代ROS1/NTRK抑制剂Augtyro（瑞普替尼）和全球第2款KRAS G12C抑制剂Krazati（阿达格拉西）初露头角，2024年的全球销售额分别为0.38亿美元和1.26亿美元。在后期实体瘤管线的储备中，抗岩藻糖GM1神经节苷脂（Fucosyl-GM1）单抗atigotatug（BMS-986012）承载了BMS进击小细胞肺癌的雄心，其与O药一线联合治疗广泛期小细胞肺癌的III期研究已推进至III期阶段。血液瘤领域，CD19 CAR-T疗法Breyanzi因产能扩大释放了销售潜力，翻倍增长至7.47亿美元。BCMA CAR-T疗法Abecma销售有所下滑，为4.06亿美元。全球首个红细胞成熟剂Reblozyl（罗特西普）全年销售额达17.73亿美元，高增长主要由一线骨髓增生异常综合征导致的贫血患者的需求驱动。Revlimid（来那度胺）和Pomalyst/Imnovid（泊马度胺）两代度胺类产品合计贡献93.18亿美元。未来BMS在血液瘤领域将重点攻坚多发性骨髓瘤，其精准布局的GPRC5D CAR-T疗法arlo-cel、两款分子胶iberdomide和mezigdomide均已推进至III期阶段。 NO.1 默沙东全球肿瘤免疫标杆产品Keytruda（帕博利珠单抗）再度展现“药王”的实力，2024年以18%的增长速度创收294.82亿美元，不仅贡献了默沙东全年总营收46%的份额，更助力其坐稳了肿瘤领域NO.1的位置。默沙东从晚期适应症的覆盖到早中期的前移探索，从单药到联合，以及皮下制剂的开发。就以早期肿瘤的治疗来说，K药是唯一在4项研究中显示出显著OS获益的肿瘤免疫疗法，并获得了9项适应症批准。其他肿瘤产品也均处于增长之中。全球首创HIF-2α抑制剂Welireg于2021年上市，如今似乎进入了快速放量阶段，2024年取得5.09亿美元的销售额，同比增长133%。Lynparza（奥拉帕利）和Lenvima（仑伐替尼）则分别带来了13.11亿美元和10.10亿美元的收入分成。基于现有的业务布局，默沙东认为在肿瘤领域还有250亿美元的潜在市场机会。要将这250亿美元的潜在价值转化为实际收益，ADC药物将打出关键组合拳。通过与第一三共和科伦博泰等ADC龙头企业的合作，默沙东快速收获了一系列管线，覆盖HER3、B7-H3、CDH6和TROP2诸多潜力靶点。其中，HER3-DXd已申报上市。 PART.02 2024年肿瘤产品销售额TOP3 No.3 / Opdivo（纳武利尤单抗） 2024年，BMS的Opdivo（纳武利尤单抗）销售收入93.04亿美元，加上来自小野制药的8.40亿美元，总销售额达到101.44亿美元。纳武利尤单抗目前已在包括美国、欧盟、日本和中国在内的超过65个国家和地区获得批准上市，涵盖12个瘤种，包括肺癌、头颈癌、胃癌、食管癌、肝癌、肾癌、结直肠癌、尿路上皮癌、黑色素瘤、霍奇金淋巴瘤、胸膜肿瘤、不明原发部位肿瘤。纳武利尤单抗的专利将于2028年到期，BMS正通过推出皮下制剂等方式延长产品生命周期。2024年12月28日，FDA批准了Opdivo皮下注射剂Opdivo Qvantig（nivolumab加透明质酸酶）上市，用于所有已批准的Opdivo适应症，意味着Opdivo成为全球首款获批上市的PD-1皮下制剂。 No.2 / Darzalex（达雷妥尤单抗）强生的达雷妥尤单抗（Darzalex）作为治疗多发性骨髓瘤的靶向CD38单抗，2024年全球销售额达116.70亿美元，同比增长19.8%，首次突破百亿美元大关。达雷妥尤单抗的组合物专利将于2026年3月到期，国内药企中，正大天晴、复宏汉霖、九源基因都有在研的生物类似药。 No.1 / Keytruda（帕博利珠单抗） 2023年的药王Keytruda（帕博利珠单抗）营收高达294.82亿美元，同比增长18%，其销售额约占默沙东全年总营收的46%，成功卫冕2024年的全球药王。2024其增长主要源于全球范围内对转移适应症的需求持续强劲，包括新增膀胱癌、子宫内膜癌适应症以及包括三阴性乳腺癌和非小细胞肺癌等在内的早期适应症。不过，K药的部分关键专利将在2028年到期，生物类似药的涌入和国产PD-1的“出海”都将蚕食其市场份额。 2024年全球制药肿瘤行业排名TOP10的出炉，不仅展现了各家药企在肿瘤领域的实力，也为未来肿瘤治疗的发展指明了方向。免疫治疗发展迅速，联合治疗方式因其显著疗效而逐渐成为研究热点。此外，部分药企借助AI技术辅助药物研发，加速了药物研发的速度，也提升了治疗方案的精准性。 END 参考来源：1、2024年全球制药巨头肿瘤业务排名TOP10 https://mp.weixin.qq.com/s/MKFoIGw04PieE5A8Jzn2bQ 2、谁是肿瘤药之王?2024年全球肿瘤药品TOP3https://mp.weixin.qq.com/s/BTaHwf13fUWJBhEaBedbSw 声明：本文仅代表作者个人观点，不代表任何组织及本公众号立场，如有不当之处，敬请指正。如需转载，请注明作者及来源：蒲公英Biopharma。

免疫疗法细胞疗法抗体药物偶联物并购

2025-03-06

·PRNewswire

TEPMETKO Continues to Strengthens its Position as a Leading METex14 Skipping NSCLC Therapy | DelveInsight

With increasing biomarker-driven cancer treatments, TEPMETKO benefits from growing adoption in precision oncology. Competition from other MET inhibitors like TABRECTA (capmatinib) exists, but TEPMETKO's once-daily dosing and efficacy profile offer differentiation. LAS VEGAS, March 6, 2025 /PRNewswire/ -- DelveInsight's " TEPMETKO Market Size, Forecast, and Market Insight Report" highlights the details around TEPMETKO, a kinase inhibitor indicated for the treatment of adult patients with metastatic NSCLC harboring MET exon 14 skipping alterations. The report provides product descriptions, patent details, and competitor products (marketed and emerging therapies) of TEPMETKO. The report also highlights the historical and forecasted sales from 2020 to 2034 segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. EMD Serono's TEPMETKO (tepotinib) Overview TEPMETKO is a kinase inhibitor prescribed for adult patients with metastatic non-small cell lung cancer (NSCLC) carrying MET exon 14 skipping alterations. The active component is Tepotinib (as hydrochloride monohydrate), administered orally. Patients should be cautioned about the heightened risk of severe or fatal interstitial lung disease/pneumonitis, liver toxicity, and potential embryo-fetal toxicity, necessitating effective contraception during and shortly after treatment. Tepotinib specifically targets MET, including variants with exon 14 skipping mutations. It blocks HGF-dependent and independent MET phosphorylation, disrupting MET-driven signaling pathways. Additionally, at clinically relevant concentrations, Tepotinib inhibits melatonin 2 and imidazoline 1 receptors. In vitro studies show that it suppresses tumor cell proliferation, anchorage-independent growth, and migration of MET-dependent cancer cells. In mouse models with MET-driven tumors, including those with MET exon 14 skipping alterations, Tepotinib reduced tumor growth, sustained MET phosphorylation inhibition, and, in one case, decreased metastasis formation. The recommended dose of TEPMETKO is 450 mg taken orally once daily until disease progression or intolerable toxicity occurs. Patients should take it at the same time each day, swallowing tablets whole without chewing, crushing, or splitting them. If a dose is missed and less than eight hours remain until the next scheduled dose, patients should skip it. In cases of vomiting after taking TEPMETKO, the next dose should be taken at the usual time. Learn more about TEPMETKO projected market size for NSCLC @ TEPMETKO Market Potential Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 81% of all diagnosed cases. Early detection greatly improves outcomes, but diagnosing NSCLC and other lung cancers is challenging because their symptoms are often mistaken for common illnesses or the long-term effects of smoking. Consequently, 80% of NSCLC cases are already at advanced stages by the time they are identified, making treatment more difficult. Around 80% of EGFR mutations in NSCLC involve either exon 19 deletions or the exon 21 L858R substitution, both of which are classified as sensitizing mutations. Until the last decade, chemotherapy was the primary treatment for advanced and metastatic lung cancer. However, this changed in 2015 with the approval of the first immune checkpoint inhibitor (ICI), KEYTRUDA (pembrolizumab), as a second-line therapy for advanced cases. This was followed by TECENTRIQ (atezolizumab) in 2016. Both therapies were later approved for first-line treatment, broadening their use to a larger patient population. In 2020, the combination of OPDIVO (nivolumab) and ipilimumab also received approval as a first-line treatment for metastatic NSCLC. According to DelveInsight, the NSCLC market size across the 7MM is projected to grow from USD 30 billion in 2024, with a substantial CAGR through 2034. This growth is largely driven by the introduction of emerging therapies during the forecast period (2025–2034). Discover more about the NSCLC market in detail @ Non-small Cell Lung Cancer Market Report Emerging Competitors of TEPMETKO The NSCLC pipeline is very robust with the promising therapies such as Telisotuzumab vedotin (AbbVie), Patritumab deruxtecan (Daiichi Sankyo/AstraZeneca), Datopotamab deruxtecan (Daiichi Sankyo/AstraZeneca), Eftilagimod alpha (Immutep), BNT311/GEN1046 (acasunlimab) (Genmab), V940 (mRNA-4157) + Pembrolizumab (Moderna Therapeutics/Merck), Plinabulin + Docetaxel (BeyondSpring), Olomorasib (LY3537982) (Eli Lilly and Company), Zipalertinib (Cullinan Oncology/Taiho Pharma), Ceralasertib (AZD6738) (AstraZeneca), TEDOPI (EP-2101; IDM 2101; OSE-2101) (OSE Immuno-therapeutics), Sigvotatug vedotin (PF08046047) (Pfizer), ANKTIVA (N-803) (ImmunityBio), Aumolertinib/Almonertinib/HS-10206 (Jiangsu Hansoh Pharmaceutical), Niraparib (GSK), Savolitinib (AstraZeneca/Hutchison MediPharma), TRODELVY (Gilead Sciences), Pyrotinib (Jiangsu HengRui Medicine), Ociperlimab (BGB-A1217) (BieGene), Volrustomig (AstraZeneca), Gotistobart (BNT316/ONC-392) (OncoC4/BioNTech), Ivonescimab (AK112/SMT112) (Akeso Biopharma/Summit Therapeutics), ZYNYZ (retifanlimab/INCMGA00012) (Incyte/Macrogenics), Divarasib (GDC-6036) (Roche/Genentech), Tiragolumab (RG6058) (Roche), Sacituzumab Tirumotecan (Merck and Kelun-Biotech), JEMPERLI (dostarlimab/TSR-042) (GSK and AnaptysBio), Zongertinib (BI-1810631) (Boehringer Ingelheim), BAY 2927088 (Bayer), Serplulimab (HLX10) (Shanghai Henlius Biotech), Rilvegostomig (AZD2936) (AstraZeneca), MK-1084 (Merck, Taiho Pharmaceutical, and Astex), Domvanalimab (Arcus Biosciences and Gilead Sciences), OPDUALAG (nivolumab and relatlimab) (Bristol-Myers Squibb), Belrestotug + JEMPERLI (iTeos Therapeutics and GSK), Firmonertinib (ArriVent BioPharma), Sunvozertinib (DZD9008) (Dizal Pharmaceutical), Cobolimab (GSK), Livmoniplimab (AbbVie), Fianlimab (REGN3767) (Regeneron Pharmaceuticals), BNT327/PM8002 (Biotheus/BioNTech), HS-20117 (Hansoh BioMedical), IO102-IO103 + Pembrolizumab (IO Biotech), Naptumomab estafenatox (NeoTX Therapeutics/Active Biotech), FF-10832 (FUJIFILM Corporation), BNT116 (BioNTechSE/Regeneron Pharmaceuticals), CAN-2409 (Candel Therapeutics), Mecbotamab Vedotin (BA3011/CAB-AXL-ADC) (BioAtla), Bemcentinib (BGB 324/BGB-3234/R-428) (BerGenBio/Rigel Pharmaceuticals), DOVBLERON (taletrectinib/AB-106/IBI-344) (Nuvation Bio/Innovent Biologics/Daiichi Sankyo/Nippon Kayaku), Lifileucel (Iovance Biotherapeutics), IBI363 (Innovent Biologics), Sotevtamab (AB-16B5) (Alethia Biotherapeutics), Avutometinib (VS6766) (Verastem Oncology), Vebreltinib (APL-101) (Apollomics), LP-300 (Lantern Pharma), JNJ-90301900 (Johnson & Johnson Innovative Medicine), AMG 193 (Amgen), Luveltamab tazevibulin (Sutro Biopharma), PRT3789 (Prelude Therapeutics), Disitamab vedotin (Seagen), PADCEV (enfortumab vedotin) (Astellas Pharma), RP1 (Replimune), TIVDAK (tisotumab vedotin) (Seagen), Zanidatamab (Jazz Pharmaceuticals), Utidelone injectable (UTD1) (Beijing Biostar Pharmaceuticals), REGN5093-M114 (Regeneron Pharmaceuticals), SLC-391 (SignalChem Lifesciences), fulzerasib (GenFleet), Davutamig (REGN5093) (Regeneron Pharmaceuticals), TAS3351 (Taiho Oncology), H002 (RedCloud Bio), JIN-A02 (J INTS BIO), FWD1509 (Forward Pharma), Sabestomig (AZD7789) (AstraZeneca), Sasanlimab (Pfizer), Selvigaltin (GB1211) (Galecto Biotech), Vepafestinib Helsinn (Healthcare/Taiho Pharmaceutical), EP0031 (A400/ KL590586) (Ellipses Pharma/Kelun-Biotech), Pamvatamig (MCLA-129) (Merus), Zidesamtinib (NVL-520) (Nuvalent), NVL-655 (Nuvalent), RMC-4630 (Revolution Medicines), REQORSA (quaratusugene ozeplasmid) (Genprex), PDC*lung01 (PDC*line Pharma), Evalstotug (BA3071) (BioAtla and BeiGene), PT-112 (Promontory Therapeutics), MRT-2359 (Monte Rosa Therapeutics), GAIA-102 (GAIA BioMedicine), Rigosertib (Traws Pharma), HMBD-001 (Hummingbird Bioscience), PLB1004 (Avistone Biotechnology), ANS03 (Avistone Biotechnology), MYTX-011 (Mythic Therapeutics), A166 (Sichuan Kelun-Biotech Bio-pharmaceutical), Atamparib (BN-2397) (Ribon Therapeutics), DELTACEL (KB-GDT-01) (Kiromic BioPharma), Carotuximab (ENV-105) (Kairos Pharma), YL202 (MediLink Therapeutics), and others. To know more about the number of competing drugs in development, visit @ TEPMETKO Market Positioning Compared to Other Drugs Key Milestones of TEPMETKO In February 2024, the FDA granted traditional approval to TEPMETKO for adult patients with metastatic NSCLC harboring MET exon 14 skipping alterations. In February 2022, the EC approved TEPMETKO as monotherapy for the treatment of adult patients with advanced NSCLC harboring alterations leading to METex14 skipping who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy. In February 2021, Merck announced that the US FDA has approved TEPMETKO following priority review for the treatment of adult patients with metastatic NSCLC harboring MET exon 14 skipping alterations. This indication was approved under accelerated approval based on ORR and DOR. In October 2020, TEPMETKO received ODD for treating NSCLC with MET genomic tumor aberrations In March 2020, EMD Serono (the biopharmaceutical business of Merck KGaA), announced that the MHLW approved TEPMETKO for the treatment of patients with unresectable, advanced, or recurrent NSCLC with METex14 skipping alterations. In September 2019, the US FDA granted BTD for tepotinib in patients with metastatic NSCLC harboring METex14 skipping alterations who progressed following platinum-based cancer therapy Discover how TEPMETKO is shaping the NSCLC treatment landscape @ TEPMETKO NSCLC TEPMETKO Market Dynamics TEPMETKO competes in a growing but highly specialized market where MET-targeted therapies are gaining traction due to their efficacy in addressing MET-altered tumors. The market for MET inhibitors is expanding as precision oncology advances and molecular diagnostics become more widely available, enabling better identification of patients who would benefit from targeted treatments like TEPMETKO. A key factor shaping TEPMETKO's market dynamics is competition. It directly competes with Novartis' TABRECTA (capmatinib), another MET inhibitor approved for the same indication. While TEPMETKO offers the advantage of once-daily dosing compared to TABRECTA's twice-daily regimen, both drugs have similar efficacy profiles, making physician and patient preference an important differentiator. Additionally, broader competition from next-generation MET inhibitors and combination therapies in clinical trials could impact TEPMETKO's long-term market position. Regulatory approvals and market access play a crucial role in TEPMETKO's adoption. The drug has been approved in multiple regions, including the U.S., Europe, and Japan, but reimbursement and pricing strategies vary by market. Payer policies, along with the cost-benefit analysis of MET inhibitors compared to other targeted therapies, influence prescription trends. Furthermore, real-world evidence and post-marketing studies will be critical in demonstrating TEPMETKO's sustained effectiveness and safety, which could support expanded indications and increased market penetration. Looking ahead, the MET inhibitor market is expected to grow with advances in biomarker-driven therapy, further refining patient selection. TEPMETKO's success will depend on continued clinical development, potential label expansions, and strategic partnerships to strengthen its competitive edge. As new entrants emerge, Merck KGaA's ability to differentiate TEPMETKO through combination strategies or enhanced formulations may determine its long-term sustainability in this evolving landscape. Dive deeper to get more insight into TEPMETKO's strengths & weaknesses relative to competitors @ TEPMETKO Market Drug Report Table of Contents Related Reports Non-small Cell Lung Cancer Market Non-small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NSCLC companies including Daiichi Sankyo, AstraZeneca, Gilead Sciences, BieGene, AbbVie, Roche, Merck, Novartis, Pfizer, Takeda Pharmaceuticals, Eli Lilly, BerGenBio, GlaxoSmithKline, Duality biologics, among others. Non-small Cell Lung Cancer Pipeline Non-small Cell Lung Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key non-small cell lung cancer companies, including BridgeBio Pharma, Daiichi Sankyo, EMD Serono, Merck, BridgeBio Pharma, Abbvie, Pfizer, Eli Lilly and Company BioNTech SE, Shenzhen TargetRx, Taiho Pharmaceutical, Chong Kun Dang, Bristol Myers Squibb, Innovent Biologics, Xuanzhu Biopharmaceutical, Bayer, GeneScience Pharmaceuticals, InventisBio, Apollomics, Imugene, Ono Pharmaceutical, Pierre Fabre, Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb, Surface Oncology, Inhibrx, Sinocelltech, Mirati Therapeutics, REVOLUTION Medicines, Yong Shun Technology Development, Iovance Biotherapeutics, Galecto Biotech, among others. C-MET Metastatic Non-small Cell Lung Cancer Market C-MET Metastatic Non-small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key C-MET mNSCLC companies, including Novartis, Merck, EMD Serono, AbbVie, Regeneron Pharmaceuticals, Mythic Therapeutics, Apollomics, Johnson & Johnson Innovation, Haihe Biopharma, among others. C-MET Non-small Cell Lung Cancer Pipeline C-MET Non-small Cell Lung Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key C-MET non-small cell lung cancer companies, including AbbVie, Janssen Research & Development, Beijing Pearl Biotechnology Limited Liability Company, Novartis, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

上市批准免疫疗法优先审批

100 项与瑞拉利单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11350	瑞拉利单抗	-	DB14851

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
复发性非鳞状非小细胞肺癌	临床3期	美国	Bristol Myers Squibb Co.	2024-10-07
复发性非鳞状非小细胞肺癌	临床3期	中国	Bristol Myers Squibb Co.	2024-10-07
复发性非鳞状非小细胞肺癌	临床3期	日本	Bristol Myers Squibb Co.	2024-10-07
复发性非鳞状非小细胞肺癌	临床3期	阿根廷	Bristol Myers Squibb Co.	2024-10-07
复发性非鳞状非小细胞肺癌	临床3期	澳大利亚	Bristol Myers Squibb Co.	2024-10-07
复发性非鳞状非小细胞肺癌	临床3期	奥地利	Bristol Myers Squibb Co.	2024-10-07
复发性非鳞状非小细胞肺癌	临床3期	比利时	Bristol Myers Squibb Co.	2024-10-07
复发性非鳞状非小细胞肺癌	临床3期	巴西	Bristol Myers Squibb Co.	2024-10-07
复发性非鳞状非小细胞肺癌	临床3期	智利	Bristol Myers Squibb Co.	2024-10-07
复发性非鳞状非小细胞肺癌	临床3期	哥伦比亚	Bristol Myers Squibb Co.	2024-10-07

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04552223 (phase II study of nivolumab/relatlimab, CTgov)	临床2期	葡萄膜黑色素瘤	27	Nivolumab+Relatlimab	鏇構衊鑰膚蓋鬱範餘窪 = 鹽餘鏇鹹鹽襯鑰齋淵窪獵製醖鏇鬱鹽廠鹽蓋壓 (觸艱選齋願襯憲繭範簾, 膚餘蓋範選選網範選艱 ~ 憲壓壓築淵齋醖鬱窪積) 更多	-	2025-02-13
NCT03642067 (CTgov)	临床2期	微卫星稳定型结直肠癌 \| 大肠腺癌	59	Nivolumab+Relatlimab (Cohort A: Composite PD-L1/Mucin (CPM) Positive Colorectal Cancer)	顧淵餘窪鹽遞積窪構積 = 醖憲蓋顧構顧壓獵願築壓觸願顧夢餘蓋窪夢積 (鹽醖觸鬱築鏇鹹窪窪積, 艱構觸簾網窪鑰膚淵鑰 ~ 構構製齋廠壓醖築製糧) 更多	-	2025-01-28
				Nivolumab+Relatlimab (Cohort B: Composite PD-L1/Mucin (CPM) Negative Colorectal Cancer)	顧淵餘窪鹽遞積窪構積 = 壓餘鹽鹹鏇壓襯獵淵願壓觸願顧夢餘蓋窪夢積 (鹽醖觸鬱築鏇鹹窪窪積, 齋夢獵鹹構顧築範窪憲 ~ 願選製襯鹹選繭繭壓顧) 更多
NEWS 人工标引	N/A	可切除非小细胞肺癌新辅助	-	纳武利尤单抗240 mg (PD-L1≥50%)	窪網顧觸築構構願衊觸(鑰餘鏇選遞廠齋餘壓繭) = 選淵範艱膚鏇範醖壓醖築製夢製憲鏇醖鹹餘糧 (膚齋鹽構顧顧築艱繭廠 ) 更多	积极	2025-01-20
				纳武利尤单抗240 mg + Relatlimab 80 mg (PD-L1≥50%)	窪網顧觸築構構願衊觸(鑰餘鏇選遞廠齋餘壓繭) = 鏇構鏇鹹齋壓餘鏇觸鑰築製夢製憲鏇醖鹹餘糧 (膚齋鹽構顧顧築艱繭廠 ) 更多
NCT04567615 (CTgov)	临床2期	晚期肝细胞癌	266	Nivolumab (Treatment A)	憲餘淵鹽簾顧積顧鏇襯 = 醖膚鹹繭餘壓窪憲積構蓋網構蓋製壓積衊蓋範 (餘壓廠憲餘鹽衊鬱衊繭, 夢願網蓋願簾鏇構積憲 ~ 憲積襯顧糧鏇鑰醖醖鏇) 更多	-	2024-10-08
				Nivolumab (Treatment B)	憲餘淵鹽簾顧積顧鏇襯 = 蓋鬱範繭願夢壓製簾顧蓋網構蓋製壓積衊蓋範 (餘壓廠憲餘鹽衊鬱衊繭, 憲選積蓋齋憲廠鏇餘觸 ~ 窪遞壓膚憲膚壓壓襯積) 更多
NCT03026140 (NICHE-3, Pubmed \| Nat Med) 人工标引	临床2期	错配修复缺陷或微卫星高度不稳定性结直肠癌新辅助 Deficient DNA Mismatch Repair (dMMR)	59	Nivolumab relatlimab	鑰製選鬱壓衊願壓衊製(顧鬱築膚觸鑰製簾願網) = 遞艱窪築觸鬱鏇鑰窪網壓簾選艱衊選齋艱壓構 (壓遞憲夢積鏇窪襯顧範, 81 ~ 97) 更多	积极	2024-09-15
NCT04552223 (ESMO2024) 人工标引	临床2期	葡萄膜黑色素瘤	26	Nivolumab 480 mg/relatlimab 160 mg	願積淵壓壓餘繭範糧鏇(製艱鑰鬱築製築糧積網) = 簾積簾構憲網遞鬱廠繭鏇膚簾齋鏇窪鑰構鹹憲 (選夢衊網夢齋獵憲鏇遞 ) 更多	不佳	2024-09-14
NCT03493932 (CTgov)	临床1期	胶质母细胞瘤	21	nivolumab+BMS-986016	範範範製鏇鑰襯夢範顧 = 膚膚膚觸範鏇獵顧壓願醖廠廠鑰蓋築積鑰窪憲 (壓鹹積製襯廠繭衊餘衊, 獵壓餘淵鏇醖壓艱製齋 ~ 衊夢鑰鑰觸觸觸鹽網範)	-	2024-07-24
NCT03459222 (RELATIVITY-048, ASCO2024) 人工标引	临床1/2期	局部晚期黑色素瘤一线 PD-L1 Positive \| LAG3 Positive	46	Nivolumab 480 mg Q4W	顧壓壓壓鏇獵憲鹹齋糧(壓築夢糧鹽繭鬱獵襯遞) = 繭積鹹壓構築壓餘範鹽積範夢衊醖遞鑰鑰簾鬱 (願壓鑰顧選壓艱築壓糧, 43.2–73.0) 更多	积极	2024-05-24
NCT03642067 (ASCO2024) 人工标引	临床2期	微卫星稳定型结直肠癌 Microsatellite Stable (MSS)	59	Nivolumab/Relatlimab	遞範鹽壓顧觸齋網鑰製(糧餘築範觸範鬱鑰廠膚) = 築鬱醖蓋鑰製鏇憲餘蓋積製糧鹽糧積餘顧餘艱 (鏇鑰醖夢鏇餘窪衊醖憲 ) 未达到更多	不佳	2024-05-24
				Nivolumab 480mg/Relatlimab 160mg	膚鬱淵選壓衊築積鏇糧(鏇鹹壓襯壓願蓋鏇糧餘) = 襯鑰製齋襯鏇淵壓積鑰範壓製膚鬱網構繭積淵 (夢壓壓蓋艱遞簾壓淵鑰 ) 更多
NCT03743766 (ASCO2024) 人工标引	临床2期	黑色素瘤一线 BRAF Mutation	43	Nivolumab	觸醖築願齋選餘夢壓壓(齋簾齋積觸積夢遞膚窪) = 鏇鹹網顧積鑰壓鏇獵窪鑰壓壓築鬱遞鏇觸窪鬱 (積範壓簾鹽製獵願鏇獵 ) 更多	积极	2024-05-24
				Relatlimab	觸醖築願齋選餘夢壓壓(齋簾齋積觸積夢遞膚窪) = 遞壓鑰襯範獵觸簾鬱蓋鑰壓壓築鬱遞鏇觸窪鬱 (積範壓簾鹽製獵願鏇獵 ) 更多